Altimmune, Inc.
ALT · XNASCIK 1326190fmd_1B99AQBX1JJGTYZNX37BK7FNBDManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Sep 30, 2026, 66 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 3 | 11 | 10 | 6 | 8 | 4 | (0) | 0 | 0 | 0 |
| Net interest income | 0 | – | – | – | – | – | – | – | – | – |
| Research and development | 7 | 18 | 18 | 18 | 50 | 75 | 71 | 66 | 82 | 66 |
| Total operating expenses | 14 | 63 | 53 | 27 | 63 | 101 | 88 | 96 | 103 | 95 |
| Operating income | (11) | (52) | (43) | (21) | (55) | (97) | (88) | (96) | (103) | (94) |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Interest and investment income | 0 | 0 | 0 | 1 | 0 | 0 | 3 | 7 | 8 | 8 |
| Other non-operating income (expense) | 0 | (0) | (2) | 1 | 0 | (0) | 3 | 7 | 8 | 6 |
| Income before taxes | (11) | (52) | (45) | (21) | (54) | (97) | (85) | (88) | (95) | (89) |
| Income tax expense | 0 | (6) | (6) | (0) | (5) | – | (0) | – | – | (1) |
| Net income from continuing operations | (11) | (46) | (39) | (21) | (49) | – | (85) | – | – | (88) |
| Net income | (11) | (46) | (39) | (21) | (49) | (97) | (85) | (88) | (95) | (88) |
| Net income to common shareholders | (11) | (51) | (42) | (21) | (49) | – | – | – | – | – |